Head-to-head · Cost-Efficiency Index
Hims & Hers vs No BS RX
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Hims & Hers
People who want a familiar, app-driven consumer brand and only need semaglutide.
Visit Hims & HersNo BS RX
Someone who wants every term and every dose level comparable without starting an intake to see a price.
Visit No BS RXThe verdict
Hims & Hers takes it, leading the Cost-Efficiency Index 83 to 82. Nationwide reach and a slick app at a mid-market semaglutide price — but an undisclosed tirzepatide price leaves part of the value equation blank. No BS RX still earns a B− — Someone who wants every term and every dose level comparable without starting an intake to see a price.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Hims & Hers.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Hims & Hers | No BS RX |
|---|---|---|
| Cost-Efficiency Index | 83/100 | 82/100 |
| Semaglutide / mo | $199/mo | $179/mo month-to-month; a separate low-dose program runs $140 |
| Tirzepatide / mo | Not disclosed | $249/mo month-to-month; a separate low-dose program runs $140 |
| Semaglutide / yr (modeled) | $2,388 | $2,148 |
| Tirzepatide / yr (modeled) | — | $2,988 |
| Coverage | All 50 states | Not disclosed |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #24 | #28 |
Hims & Hers
83/100Where the value is
- Nationwide
- Slick app experience
- Semaglutide priced up front for modeling
The tradeoffs
- Tirzepatide pricing not consistently disclosed
- Compounded supply has drawn industry-wide regulatory scrutiny
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hims in September 2025. We still list and link to Hims & Hers; you should know the letter is on the public record before you decide.
No BS RX
82/100Where the value is
- Names four dispensing pharmacies with street addresses and telephone numbers — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx
- "No Fake Intro Rate — the price on the page is the ongoing program price" is a named commitment, and the $140 in its hero really is a month-to-month rate
- Every program row prints "503A pharmacy fulfillment" and "No dose-based price changes" on the table itself
The tradeoffs
- The same $409 twelve-week block appears under three different monthly rates — an $11 saving against one and a $128 saving against another, styled identically
- The low-dose programs stop at twelve weeks; only the standard programs carry 24- and 52-week rungs
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.